INNPF Stock Chart & Stats
$12.04
<$0.01(0.06%)
At close: 4:00 PM EST
$12.04
<$0.01(0.06%)
Day’s Range― - ―
52-Week Range$1.60 - $14.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)13.00
Market Cap
$10.28M
Enterprise Value$4.95M
Total Cash (Recent Filing)$6.68M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume0
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market Cap0.48
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit0.22
Enterprise Value/Ebitda-7.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA ~90% gross margin indicates the company's formulations and drug-delivery products have low direct costs versus pricing. That margin provides durable operating leverage: if the company controls SG&A and R&D growth, it can convert top-line into sustainable profits faster than low-margin peers, supporting long-term scalability.
Conservative Leverage / Solid Asset BaseLow debt relative to equity and meaningful assets (~10.85M) give the company financial flexibility to fund operations and R&D without immediate refinancing pressure. Moderate leverage reduces liquidity risk and supports multi-month runway to execute development milestones before needing dilutive financing.
Niche Proprietary Drug-delivery FocusA focused business model around proprietary cannabinoid delivery technologies creates structural differentiation and higher barriers to entry versus generic players. Targeting both human and veterinary therapeutic applications broadens addressable markets and enables multiple commercialization pathways and partnerships over the medium term.
Bears Say
Negative And Inconsistent Cash GenerationReturn to negative operating and free cash flow signals recurring cash burn rather than self-funded growth. Inconsistent cash generation forces reliance on external capital, increasing dilution or debt, and constrains the company's ability to fund clinical development and commercialization activities sustainably over months.
Persistent Net LossesDespite high gross margins, operating expenses continue to produce negative operating profit and a negative net margin. Persistent losses erode equity and limit internal funding for R&D or commercialization, making long-term viability dependent on improved operating discipline or external financing.
Revenue Has Stalled And Recently DeclinedA reversal from multi-year growth to TTM revenue decline indicates slowing product adoption or market headwinds. Slower top-line growth reduces operating leverage, makes it harder to absorb fixed R&D and SG&A, and increases pressure on management to find new partners, indications, or markets to restore durable revenue expansion.
InnoCan Pharma News
INNPF FAQ
What was Innocan Pharma Corporation’s price range in the past 12 months?
Innocan Pharma Corporation lowest stock price was $1.60 and its highest was $14.90 in the past 12 months.
What is Innocan Pharma Corporation’s market cap?
Innocan Pharma Corporation’s market cap is $10.28M.
When is Innocan Pharma Corporation’s upcoming earnings report date?
Innocan Pharma Corporation’s upcoming earnings report date is Aug 31, 2026 which is in 42 days.
How were Innocan Pharma Corporation’s earnings last quarter?
Innocan Pharma Corporation released its earnings results on May 27, 2026. The company reported -$0.209 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.209.
Is Innocan Pharma Corporation overvalued?
According to Wall Street analysts Innocan Pharma Corporation’s price is currently Overvalued.
Does Innocan Pharma Corporation pay dividends?
Innocan Pharma Corporation does not currently pay dividends.
What is Innocan Pharma Corporation’s EPS estimate?
Innocan Pharma Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innocan Pharma Corporation have?
Innocan Pharma Corporation has 4,498,772 shares outstanding.
What happened to Innocan Pharma Corporation’s price movement after its last earnings report?
Innocan Pharma Corporation reported an EPS of -$0.209 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.4%.
Which hedge fund is a major shareholder of Innocan Pharma Corporation?
Currently, no hedge funds are holding shares in INNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Innocan Pharma Corporation
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―
Ownership Overview
0.88% Insiders
―
Mutual Funds
― Other Institutional Investors
99.12% Public Companies and
Individual Investors